← Leaderboards
John Parkinson
Thetis Pharmaceuticals, Llc
$5,120,562
Attributed
$5,120,562
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2023–25$5M$3.8M$2.5M$1.3M$0
'23
'24
'25
Funding mix
By agency
NIH$5,120,562 · 2
By mechanism
R44$5,120,562 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Pharmacologic Substance”
- Lauren Miller · Technical Resources International, Inc.$31,120,905
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Mehrinfar Mahzad · Fisher Bioservices, Inc.$18,271,500
- Bambra Stokes · Ppd Development Lp$17,155,112
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Debra Burnin · Sri International$9,413,546
Research focus
Pharmacologic SubstanceClinicSafetyRattusTherapeutic AgentsToxicologyLegal PatentInvestigational DrugsProgramsDoseGrantSide EffectToxic EffectToxicokineticsInflammationImmuneInnovationCanis FamiliarisPhase 1 StudyPharmaceutical PreparationsMalignant NeoplasmsClinical DevelopmentGlobal HealthFoundations
Grant awards (5)
Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer$1,725,203
R44 · FY2025 · CA · contact PI
Development of TP-317 in Ulcerative Colitis$999,696
R44 · FY2025 · DK · contact PI
Development of TP-317 in Ulcerative Colitis$999,624
R44 · FY2024 · DK · contact PI
Development of TP-317 in Ulcerative Colitis$997,635
R44 · FY2023 · DK · contact PI
Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer$398,404
R44 · FY2023 · CA · contact PI